← Back to Screener
Zenas BioPharma, Inc. Common Stock (ZBIO)
Price$20.90
Favorite Metrics
Price vs S&P 500 (26W)-26.69%
Price vs S&P 500 (4W)-11.65%
Market Capitalization$1.28B
All Metrics
Book Value / Share (Quarterly)$4.44
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-3.81
Price vs S&P 500 (YTD)-44.04%
EPS (TTM)$-7.80
10-Day Avg Trading Volume0.53M
EPS Excl Extra (TTM)$-7.80
EPS (Annual)$-8.44
ROI (Annual)-117.76%
Cash / Share (Quarterly)$6.30
ROA (Last FY)-98.46%
Revenue Growth TTM (YoY)100.00%
EBITD / Share (TTM)$-8.55
Cash Flow / Share (Annual)$-3.81
P/B Ratio5.28x
P/B Ratio (Quarterly)8.05x
Net Income / Employee (Annual)$-2
ROA (TTM)-113.39%
EPS Incl Extra (Annual)$-8.44
Current Ratio (Annual)5.61x
Quick Ratio (Quarterly)5.48x
3-Month Avg Trading Volume0.85M
52-Week Price Return161.94%
Revenue / Employee (TTM)$0
P/S Ratio (Annual)127.89x
Asset Turnover (Annual)0.03x
52-Week High$44.60
EPS Excl Extra (Annual)$-8.44
26-Week Price Return-17.94%
Quick Ratio (Annual)5.48x
13-Week Price Return-3.28%
Total Debt / Equity (Annual)0.32x
Current Ratio (Quarterly)5.61x
Enterprise Value$1,246.928
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-3778.16%
Cash / Share (Annual)$6.30
3-Month Return Std Dev78.30%
Net Income / Employee (TTM)$-2
ROE (Last FY)-156.00%
EPS Basic Excl Extra (Annual)$-8.44
Total Debt / Equity (Quarterly)0.32x
EPS Incl Extra (TTM)$-7.80
ROI (TTM)-135.62%
Revenue / Share (Annual)$0.22
Price vs S&P 500 (52W)126.85%
Year-to-Date Return-39.91%
5-Day Price Return3.71%
EPS Normalized (Annual)$-8.44
Net Profit Margin (Annual)-3777.37%
Month-to-Date Return11.61%
EBITD / Share (Annual)$-8.55
Operating Margin (Annual)-3830.57%
LT Debt / Equity (Annual)0.32x
LT Debt / Equity (Quarterly)0.32x
EPS Basic Excl Extra (TTM)$-7.80
P/B Ratio (Annual)8.05x
Book Value / Share (Annual)$4.44
Price vs S&P 500 (13W)-6.15%
Beta0.70x
Revenue / Share (TTM)$0.19
ROE (TTM)-156.98%
52-Week Low$8.09
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.43
4.36
4.36
4.36
Industry Peers — Pharmaceuticals(309)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
ZBIOZenas BioPharma, Inc. Common Stock | — | 100.00% | — | — | $20.90 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Zenas BioPharma is a clinical-stage biopharmaceutical company focused on treating autoimmune diseases with obexelimab, a monoclonal antibody. The drug candidate targets B cells by binding to CD19 and FcyRIIb receptors, inhibiting their disease-driving activity while preserving cell survival—a mechanism designed to provide a differentiated treatment approach. This unique profile addresses a significant gap in autoimmune disease therapy.